1
|
Talavera-Barber M, Flint K, Graber B, Dhital R, Kaptsan I, Medoro AK, Sánchez PJ, Shimamura M. Antibody Titers Against Human Cytomegalovirus gM/gN and gB Among Pregnant Women and Their Infants. Front Pediatr 2022; 10:846254. [PMID: 35813379 PMCID: PMC9259787 DOI: 10.3389/fped.2022.846254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 05/12/2022] [Indexed: 11/13/2022] Open
Abstract
Congenital CMV (cCMV) infection can affect infants born to mothers with preconceptional seroimmunity. To prevent cCMV due to nonprimary maternal infection, vaccines eliciting responses exceeding natural immunity may be required. Anti-gM/gN antibodies have neutralizing capacity in-vitro and in animal models, but anti-gM/gN antibodies have not been characterized among seroimmune pregnant women. Paired maternal and infant cord sera from 92 CMV seropositive mothers and their full-term or preterm infants were tested for anti-gM/gN antibody titers in comparison with anti-gB titers and neutralizing activity. Anti-gM/gN titers were significantly lower than anti-gB titers for all groups and did not correlate with serum neutralizing capacity. Further study is needed to determine if higher anti-gM/gN antibody titers might enhance serum neutralizing capacity among seropositive adults.
Collapse
Affiliation(s)
- Maria Talavera-Barber
- Avera McKennan Hospital and University Medical Center, Avera Research Institute, Sioux Falls, SD, United States
| | - Kaitlyn Flint
- Center for Vaccines and Immunity, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States
| | - Brianna Graber
- Center for Vaccines and Immunity, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States
| | - Ravi Dhital
- Center for Vaccines and Immunity, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States
| | - Irina Kaptsan
- Center for Vaccines and Immunity, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States
| | - Alexandra K Medoro
- Division of Neonatology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States.,Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States
| | - Pablo J Sánchez
- Division of Neonatology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States.,Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States.,Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States
| | - Masako Shimamura
- Center for Vaccines and Immunity, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.,Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States
| |
Collapse
|
2
|
Jones IKA, Haese NN, Gatault P, Streblow ZJ, Andoh TF, Denton M, Streblow CE, Bonin K, Kreklywich CN, Burg JM, Orloff SL, Streblow DN. Rat Cytomegalovirus Virion-Associated Proteins R131 and R129 Are Necessary for Infection of Macrophages and Dendritic Cells. Pathogens 2020; 9:E963. [PMID: 33228102 PMCID: PMC7699341 DOI: 10.3390/pathogens9110963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/05/2020] [Accepted: 11/17/2020] [Indexed: 12/15/2022] Open
Abstract
Cytomegalovirus (CMV) establishes persistent, latent infection in hosts, causing diseases in immunocompromised patients, transplant recipients, and neonates. CMV infection modifies the host chemokine axis by modulating chemokine and chemokine receptor expression and by encoding putative chemokine and chemokine receptor homologues. The viral proteins have roles in cellular signaling, migration, and transformation, as well as viral dissemination, tropism, latency and reactivation. Herein, we review the contribution of CMV-encoded chemokines and chemokine receptors to these processes, and further elucidate the viral tropism role of rat CMV (RCMV) R129 and R131. These homologues of the human CMV (HCMV)-encoded chemokines UL128 and UL130 are of particular interest because of their dual role as chemokines and members of the pentameric entry complex, which is required for entry into cell types that are essential for viral transmission and dissemination. The contributions of UL128 and UL130 to acceleration of solid organ transplant chronic rejection are poorly understood, and are in need of an effective in vivo model system to elucidate the phenomenon. We demonstrated similar molecular entry requirements for R129 and R131 in the rat cells, as observed for HCMV, and provided evidence that R129 and R131 are part of the viral entry complex required for entry into macrophages, dendritic cells, and bone marrow cells.
Collapse
Affiliation(s)
- Iris K. A. Jones
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Nicole N. Haese
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Philippe Gatault
- Renal Transplant Unit, 10 Boulevard Tonnellé, University Hospital of Tours, 37032 Tours, France;
| | - Zachary J. Streblow
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Takeshi F. Andoh
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
- Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA; (J.M.B.); (S.L.O.)
| | - Michael Denton
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Cassilyn E. Streblow
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Kiley Bonin
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Craig N. Kreklywich
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| | - Jennifer M. Burg
- Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA; (J.M.B.); (S.L.O.)
| | - Susan L. Orloff
- Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA; (J.M.B.); (S.L.O.)
- Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA
| | - Daniel N. Streblow
- Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, OR 97239, USA; (I.K.A.J.); (N.N.H.); (Z.J.S.); (T.F.A.); (M.D.); (C.E.S.); (K.B.); (C.N.K.)
| |
Collapse
|
3
|
Zhou P, Wu H, Chen S, Bai Q, Chen X, Chen L, Zeng X, Liu L, Chen L. MOMP and MIP DNA-loaded bacterial ghosts reduce the severity of lung lesions in mice after Chlamydia psittaci respiratory tract infection. Immunobiology 2019; 224:739-746. [DOI: 10.1016/j.imbio.2019.09.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 08/22/2019] [Accepted: 09/03/2019] [Indexed: 10/26/2022]
|
4
|
Wang H, Huang C, Dong J, Yao Y, Xie Z, Liu X, Zhang W, Fang F, Chen Z. Complete protection of mice against lethal murine cytomegalovirus challenge by immunization with DNA vaccines encoding envelope glycoprotein complex III antigens gH, gL and gO. PLoS One 2015; 10:e0119964. [PMID: 25803721 PMCID: PMC4372543 DOI: 10.1371/journal.pone.0119964] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2014] [Accepted: 01/18/2015] [Indexed: 01/13/2023] Open
Abstract
Human cytomegalovirus infects the majority of humanity which may lead to severe morbidity and mortality in newborns and immunocompromised adults. Humoral and cellular immunity are critical for controlling CMV infection. HCMV envelope glycoprotein complexes (gC I, II, III) represent major antigenic targets of antiviral immune responses. The gCIII complex is comprised of three glycoproteins, gH, gL, and gO. In the present study, DNA vaccines expressing the murine cytomegalovirus homologs of the gH, gL, and gO proteins were evaluated for protection against lethal MCMV infection in the mouse model. The results demonstrated that gH, gL, or gO single gene immunization could not yet offer good protection, whereas co-vaccination strategy apparently showed effects superior to separate immunization. Twice immunization with gH/gL/gO pDNAs could provide mice complete protection against lethal salivary gland-derived MCMV (SG-MCMV) challenge, while thrice immunization with pgH/pgL, pgH/pgO or pgL/pgO could not provide full protection. Co-vaccination with gH, gL and gO pDNAs elicited robust neutralizing antibody and cellular immune responses. Moreover, full protection was also achieved by simply passive immunization with anti-gH/gL/gO sera. These data demonstrated that gCIII complex antigens had fine immunogenicity and might be a promising candidate for the development of HCMV vaccines.
Collapse
Affiliation(s)
- Huadong Wang
- College of Life Science, Hunan Normal University, Changsha, 410081, Hunan, China
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, Hubei, China
| | - Chaoyang Huang
- College of Life Science, Hunan Normal University, Changsha, 410081, Hunan, China
| | - Jinrong Dong
- Shanghai Institute of Biological Products, Shanghai, 200052, China
| | - Yanfeng Yao
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, Hubei, China
| | - Zhenyuan Xie
- Xie Tu Community Medical Service Center, Xuhui District of Shanghai, Shanghai, 200030, China
| | - Xueying Liu
- Shanghai Institute of Biological Products, Shanghai, 200052, China
| | - Wenjie Zhang
- Xinhua Hospital affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200092, China
| | - Fang Fang
- College of Life Science, Hunan Normal University, Changsha, 410081, Hunan, China
| | - Ze Chen
- College of Life Science, Hunan Normal University, Changsha, 410081, Hunan, China
- Shanghai Institute of Biological Products, Shanghai, 200052, China
- * E-mail:
| |
Collapse
|
5
|
Schleiss MR. Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next? Future Virol 2013; 8:1161-1182. [PMID: 24523827 DOI: 10.2217/fvl.13.106] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Congenital human cytomegalovirus (HCMV) infection can lead to long-term neurodevelopmental sequelae, including mental retardation and sensorineural hearing loss. Unfortunately, CMVs are highly adapted to their specific species, precluding the evaluation of HCMV vaccines in animal models prior to clinical trials. Several species-specific CMVs have been characterized and developed in models of pathogenesis and vaccine-mediated protection against disease. These include the murine CMV (MCMV), the porcine CMV (PCMV), the rhesus macaque CMV (RhCMV), the rat CMV (RCMV), and the guinea pig CMV (GPCMV). Because of the propensity of the GPCMV to cross the placenta, infecting the fetus in utero, it has emerged as a model of particular interest in studying vaccine-mediated protection of the fetus. In this paper, a review of these various models, with particular emphasis on the value of the model in the testing and evaluation of vaccines against congenital CMV, is provided. Recent exciting developments and advances in these various models are summarized, and recommendations offered for high-priority areas for future study.
Collapse
Affiliation(s)
- Mark R Schleiss
- University of Minnesota Medical School Center for Infectious Diseases and Microbiology Translational Research Department of Pediatrics Division of Pediatric Infectious Diseases and Immunology 2001 6 Street SE Minneapolis, MN 55455-3007
| |
Collapse
|